2015
Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)
Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). The American Journal Of Cardiology 2015, 117: 186-191. PMID: 26704028, DOI: 10.1016/j.amjcard.2015.10.029.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionStrong independent predictorMajor bleedingMortality rateBivalirudin therapyCoronary interventionIndependent predictorsFemale genderGlycoprotein IIb/IIIa inhibitor treatmentST-segment elevation myocardial infarctionNon-coronary artery bypassPatient-level pooled analysisImpact of bleedingMajor bleeding ratesPronounced clinical benefitOutcomes of patientsAcute coronary syndromeCohort of patientsElevation myocardial infarctionArtery bypassCoronary syndromeMultivariate adjustmentStandard therapyClinical benefitPooled analysis
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskPredictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage
Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. Circulation 2010, 121: 853-862. PMID: 20142447, DOI: 10.1161/circulationaha.109.877944.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeAcute coronary syndrome patientsCoronary syndrome patientsComposite ischemiaCoronary syndromeAngiographic screeningCoronary ectasiaIschemic outcomesJeopardy scoreSyndrome patientsUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsAcute coronary syndrome populationPrevious percutaneous coronary interventionIIb/IIIa inhibitorsComposite ischemic eventsEarly invasive approachAdverse cardiac eventsOutcomes of patientsPercutaneous coronary interventionPredictors of outcomeTraditional clinical parametersAcute CatheterizationBivalirudin therapyMajor bleeding